Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 54

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 54
---
 incur significant losses for the foreseeable
future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our
product candidates and now that we are no longer an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933,
as amended. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank
Act, as well as rules adopted, and to be adopted, by the SEC and The Nasdaq Stock Market LLC. We also expect that compliance with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and increased disclosure requirements will increase our legal
and financial compliance costs. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and
our ability to generate revenues, if any. The costs of advancing product candidates into each clinical phase tend to increase substantially
over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing
approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical
product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to
begin generating revenue from the commercialization of any products or achieve or maintain profitability.

The costs of advancing product
candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the
total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because
of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing
or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products
or achieve or maintain profitability.

Furthermore,
our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial
additional risks and uncertainties. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable
future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity
and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability
to